BMO Capital Initiates Coverage On Taysha Gene Therapies with Outperform Rating, Announces Price Target of $5
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has initiated coverage on Taysha Gene Therapies (NASDAQ:TSHA) with an Outperform rating and a price target of $5.
June 27, 2024 | 9:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has initiated coverage on Taysha Gene Therapies with an Outperform rating and a price target of $5.
The initiation of coverage with an Outperform rating and a specific price target of $5 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100